SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-020249
Filing Date
2022-05-23
Accepted
2022-05-23 16:16:39
Documents
15
Period of Report
2022-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20004306x2_8k.htm   iXBRL 8-K 51755
2 EXHIBIT 2.1 ny20004306x2_ex2-1.htm EX-2.1 467957
3 EXHIBIT 10.1 ny20004306x2_ex10-1.htm EX-10.1 40825
4 EXHIBIT 99.1 ny20004306x2_ex99-1.htm EX-99.1 29145
  Complete submission text file 0001140361-22-020249.txt   854253

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ettx-20220523.xsd EX-101.SCH 3926
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ettx-20220523_lab.xml EX-101.LAB 23288
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ettx-20220523_pre.xml EX-101.PRE 16552
9 EXTRACTED XBRL INSTANCE DOCUMENT ny20004306x2_8k_htm.xml XML 4230
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38670 | Film No.: 22951793
SIC: 2834 Pharmaceutical Preparations